NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.

Related Keywords

California ,United States ,Alexey Danilov ,Toni Stephenson Lymphoma Center ,Hematopoietic Cell Transplantation ,Nx 2127 ,B Cell Malignancies ,Hematologic Malignancies ,Dual Function Small Molecule Degrader ,Phasei Nx 2127 001 Trial ,Cash ,Ash Annual Meeting ,D ,Phd ,City Of Hope ,